These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 19952320)

  • 1. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
    Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
    JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
    Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
    J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Yoshita H; Hosokawa A; Ueda A; Ando T; Kajiura S; Kato H; Kawabe H; Tomizawa G; Horikawa N; Yabuhita K; Note M; Sugiyama T
    Digestion; 2014; 89(1):43-8. PubMed ID: 24458112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
    Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab.
    Boonsirikamchai P; Asran MA; Maru DM; Vauthey JN; Kaur H; Kopetz S; Loyer EM
    AJR Am J Roentgenol; 2011 Dec; 197(6):W1060-6. PubMed ID: 22109320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.
    Tanaka K; Nakagawa K; Yabushita Y; Hiroshima Y; Matsuo K; Ota M; Ichikawa Y; Taguri M; Tanabe M; Koda K; Endo I
    Surgery; 2014 May; 155(5):936-44. PubMed ID: 24656858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
    Tan MC; Linehan DC; Hawkins WG; Siegel BA; Strasberg SM
    J Gastrointest Surg; 2007 Sep; 11(9):1112-9. PubMed ID: 17623263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
    Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
    Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.
    Vera R; Gomez Dorronsoro M; Lopez-Ben S; Viudez A; Queralt B; Hernandez I; Ortiz-Duran MR; Zazpe C; Soriano J; Amat I; Herrera Cabezón J; Diaz E; Codina-Barreras A; Hernandez-Yagüe X; Quera A; Figueras J
    Clin Transl Oncol; 2014 Aug; 16(8):739-45. PubMed ID: 24338508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases.
    Wesdorp NJ; Kemna R; Bolhuis K; van Waesberghe JHTM; Nota IMGC; Struik F; Oulad Abdennabi I; Phoa SSKS; van Dieren S; van Amerongen MJ; Chapelle T; Dejong CHC; Engelbrecht MRW; Gerhards MF; Grünhagen D; van Gulik TM; Hermans JJ; de Jong KP; Klaase JM; Liem MSL; van Lienden KP; Molenaar IQ; Patijn GA; Rijken AM; Ruers TM; Verhoef C; de Wilt JHW; Swijnenburg RJ; Punt CJA; Huiskens J; Stoker J; Kazemier G;
    Radiol Imaging Cancer; 2022 May; 4(3):e210105. PubMed ID: 35522139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.